Name | Abrocitinib |
Description | Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2). |
In vitro | Abrocitinib inhibits IFN-stimulated phosphorylation of STAT1 in human whole blood (HWB), IFNα-stimulated phosphorylation of STAT3, as well as pSTAT5 in CD34+ spiked into HWB (JAK2), with IC50s of 163, 189 nM, 7.178 μM, respectively. |
In vivo | In the rat adjuvant-induced arthritis model, Abrocitinib (5, 15, 50 mg/kg, p.o., daily for 7 days) significantly reduces paw swelling. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 120 mg/mL (371.05 mM), Sonication is recommended.
|
Keywords | inhibit | PF04965842 | Inhibitor | JAK | Janus kinase | Abrocitinib | PF 04965842 |
Inhibitors Related | Delgocitinib | Deucravacitinib | Fedratinib | RO8191 | Ruxolitinib | Tofacitinib Citrate | CEP-33779 | Ruxolitinib phosphate | JAK-IN-10 | Baricitinib | Tofacitinib | Ritlecitinib |
Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |